MITOTOX

Drug

D1421 | Erythromycin

Properties

Molecular Formula	C37H67NO13
Molecular Weight	733.9
Structure
State	solid
Clearance	CL (l/h/kg) in healthy subjects: 0.53 ± 0.13 after a 125mg intravenous dose [A174457] .
Volume of distribution	Erythromycin readily diffuses into the majority of body fluids and is found to accumulate in leucocytes [A174448], [F3322]. Only low concentrations are usually reached in the spinal fluid, however the passage of erythromycin throughthe blood-brain barrier increases in meningitis, likely due to the presence of inflamed tissues [F3322].
Route of elimination	In patients with normal hepatic function, erythromycin is concentrated in the liver and excreted in the bile [F3322]. Less than 5% of the orally administered dose of erythromycin is excreted in active form in the urine [F3322]. A large proportion of the absorbed drug remains unaccounted for and is presumably metabolized, probably in the liver [F3322].
Protein binding	93% serum protein binding (erythromycin propionate) [A174454].
Half life	3.5 h [A174451] In patients with liver disease, the half-life has been shown to be significantly increased, however, this is of little clinical significance [F3322].
Absorption	Orally administered erythromycin stearate is readily and reliably absorbed. Optimal serum levels of erythromycin are reached when it is taken in the fasting state or immediately before meals [F3322]. Erythromycin is well known for its highly variable bioavailability (18-45%) [A174451] after oral ingestion and its susceptibility to be degraded under acidic conditions [A174448].
Trade names	Eryc, Erythrocin
Description	antibiotic

Therapeutic Classification Source: DrugBank

S01AA17 Erythromycin

[S01AA] Antibiotics

[S01A] ANTIINFECTIVES

[S01] OPHTHALMOLOGICALS

[S] Sensory organs

J01FA01 Erythromycin

[J01FA] Macrolides

[J01F] MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS

[J01] ANTIBACTERIALS FOR SYSTEMIC USE

[J] Antiinfectives for systemic use

D10AF52 Erythromycin, combinations

[D10AF] Antiinfectives for treatment of acne

[D10A] ANTI-ACNE PREPARATIONS FOR TOPICAL USE

[D10] ANTI-ACNE PREPARATIONS

[D] Dermatological drugs

D10AF02 Erythromycin